DH
DH.US Definitive Healthcare Corp
- Market cap
- USD 140M
- P/E
- -
- P/B
- 0.92x
- ROE
- -135.7%
- Dividend yield
- 2.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DH.US undervalued?
Graham numberThe Graham number of Definitive Healthcare Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Definitive Healthcare Corp fundamental analysis
No fundamental analysis for Definitive Healthcare Corp yet.
Definitive Healthcare Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Definitive Healthcare Corp
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical resear…
Full company profileDefinitive Healthcare Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Definitive Healthcare Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 85.5M | 118M | 166M | 223M | 251M | 252M | 242M | 221M |
| Gross Profit | 42.5M | 87.8M | 125M | 180M | 204M | 197M | 183M | 155M |
| Operating Income | -2.18M | -15.9M | -27.3M | -44.0M | -330M | -711M | -20.6M | -22.1M |
| EBITDA | 15.5M | 43.5M | 23.1M | 26.2M | -241M | -567M | -142M | -221M |
| Net Income | -36.4M | -52.6M | -51.9M | -7.22M | -202M | -413M | -139M | -197M |
| EPS | -0.24 | -0.54 | -0.53 | -0.07 | -1.79 | -3.54 | -1.30 | -1.85 |
| Balance Sheet | ||||||||
| Total Assets | 1.72B | 1.75B | 2.12B | 2.12B | 1.83B | 1.09B | 735M | 489M |
| Total Liabilities | 505M | 550M | 618M | 641M | 627M | 482M | 357M | 300M |
| Shareholders' Equity | 1.22B | 1.20B | 871M | 949M | 861M | 444M | 281M | 145M |
| Cash & Short-term Investments | 8.62M | 24.8M | 387M | 332M | 308M | 290M | 181M | 190M |
| Total Debt | 439M | 462M | 271M | 276M | 268M | 253M | 173M | 164M |
| Cash Flow | ||||||||
| Operating Cash Flow | 21.6M | 23.2M | 25.2M | 35.6M | 41.2M | 58.2M | 53.8M | 45.9M |
| Capital Expenditure | 1.90M | 1.40M | 6.73M | 8.33M | 2.98M | 12.3M | 16.7M | 11.4M |
| Free Cash Flow | 19.7M | 21.8M | 18.5M | 27.3M | 38.2M | 45.9M | 37.1M | 34.5M |
| Ratios | ||||||||
| ROE | -3.0% | -4.4% | -6.0% | -0.8% | -23.5% | -93.0% | -49.4% | -135.7% |
| ROA | -2.1% | -3.0% | -2.5% | -0.3% | -11.1% | -37.9% | -18.9% | -40.4% |
| Net Profit Margin | -42.6% | -44.5% | -31.2% | -3.2% | -80.5% | -163.8% | -57.5% | -89.2% |
| Debt to Equity | 0.36x | 0.39x | 0.31x | 0.29x | 0.31x | 0.57x | 0.61x | 1.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Definitive Healthcare Corp dividends
- Dividend yield
- 2.24%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 3.15M | 0.03 | - |
| 2024 | USD 5.14M | 0.04 | - |
| 2023 | USD 12.3M | 0.11 | - |
| 2022 | USD 12.9M | 0.13 | - |
| 2021 | USD 8.13M | 0.08 | - |
| 2020 | USD 2.94M | 0.03 | - |
| 2019 | USD 6.96M | 0.05 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Definitive Healthcare Corp
- Insiders 6.17%
- Institutions 82.16%
- Public & others 11.68%
- Shares outstanding 107M
- Free float 40.8M
Top funds holding DH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.33M | 1.24% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 431K | 0.40% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 275K | 0.26% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 219K | 0.20% | -0.38% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 204K | 0.19% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 204K | 0.19% | 0.00% | Oct 2026 |
| WisdomTree US SmallCap Earnings ETF | 115K | 0.11% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 111K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 96.2K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 71.2K | 0.07% | 0.00% | Aug 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 71.0K | 0.07% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 68.8K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 55.7K | 0.05% | +0.16% | Sep 2026 |
| NVIT Small Cap Val I | 54.2K | 0.05% | 0.00% | Jun 2026 |
| North Square Kennedy MicroCap I | 51.2K | 0.05% | 0.00% | Jun 2026 |
| Strategic Advisers U.S. Total Stock | 29.9K | 0.03% | -20.21% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 29.9K | 0.03% | 0.00% | Sep 2026 |
| MGI Acadian Glb Eq III C2-0.75-NOK Acc | 26.2K | 0.02% | 0.00% | Jun 2026 |
| NVIT Multi-Manager Small Company I | 25.5K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 24.8K | 0.02% | -0.40% | Sep 2026 |
Top institutions holding DH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Advent International LP | 62.5M | 58.45% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 5.96M | 5.57% | -1.40% | Jun 2026 |
| D. E. Shaw & Co LP | 1.97M | 1.85% | -6.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.83M | 1.71% | -1.98% | Jun 2026 |
| Kennedy Capital Management Inc | 1.74M | 1.62% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.41M | 1.32% | -52.82% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.40M | 1.31% | -3.80% | Sep 2026 |
| AQR Capital Management LLC | 899K | 0.84% | +28.08% | Jun 2026 |
| CWM Advisors, LLC | 895K | 0.84% | +91.15% | Jun 2026 |
| Geode Capital Management, LLC | 551K | 0.52% | -53.31% | Jun 2026 |
| GSA Capital Partners LLP | 526K | 0.49% | +56.66% | Jun 2026 |
| Renaissance Technologies Corp | 525K | 0.49% | +2.72% | Jun 2026 |
| Two Sigma Investments LLC | 509K | 0.48% | +118.05% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 473K | 0.44% | +57.85% | Jun 2026 |
| CI Private Wealth LLC | 454K | 0.43% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 449K | 0.42% | +120.65% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 404K | 0.38% | -5.79% | Jun 2026 |
| Squarepoint Ops LLC | 352K | 0.33% | +46.53% | Jun 2026 |
| Barclays PLC | 324K | 0.30% | -0.86% | Jun 2026 |
| Millennium Management LLC | 276K | 0.26% | -53.27% | Jun 2026 |
Definitive Healthcare Corp company profile
- Company name
- Definitive Healthcare Corp
- Ticker
- DH.US
- Exchange
- USA Stocks
- Listed since
- Sep 15, 2021
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 678
- Fiscal year end
- December
- Address
- 492 Old Connecticut Path, Framingham, MA, United States, 01701
- Phone
- 508 720 4224
- Website
- definitivehc.com
About Definitive Healthcare Corp
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, marketing and advertising agencies.Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Definitive Healthcare Corp management
9- Mr. Jason Ronald KrantzFounder & Executive Chairman · born 1974
- Ms. Casey HellerChief Financial Officer · born 1989
- Mr. Clay RitcheyCEO & Director · born 1971
- Mr. Jonathan Paris J.D.Chief Legal Officer & Secretary · born 1975
- Ms. Marissa Peoples OdellSVP & Head of Sales
- Ms. Jeannine Lombardi SheehanChief Human Resources Officer · born 1974
- Ms. Rebecca MaraniChief Product Officer
- Ms. Sally SlarkeSenior Vice President of Commercial Center of Excellence
- Mr. Srinivas AttipalliSenior VP and Head of AI & Data - Product